Program
VP-102
Also written as “VP-102 - Cantharidin, Topical Film Forming Solution”, “VP-102 (US) / TO-208 (Japan)” and “VP-102 and applicator”.
Its studies are mostly in Warts · Molluscum Contagiosum · Condylomata Acuminata, led by Verrica Pharmaceuticals.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Verrica Pharmaceuticals | 83 open or running | phase 3since Dec 13, 2017 | Jun 12, 2017 | Nov 2026phase 3 · NCT07246590 |
Also a collaborator on its studies: canfield-scientific-inc, medidata-solutions, veeva-systems, allucent-us-llc, myonex, cmic-co-ltd-japan, paidion-research-inc, bioclinica-inc, almac-clinical-services, database-integrations-inc, cato-research and instat-services.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Jun 12, 2017First study: phase 2 study in Molluscum ContagiosumFirst studyNCT03186378 · 33 enrolled · United States
- Dec 13, 20172 phase 3 studies in Molluscum ContagiosumNCT03377803, NCT03377790
- Mar 21, 2018Phase 2 study in WartsNCT03487549 · 56 enrolled · United States
- Jun 6, 2019Phase 2 study in Condylomata AcuminataNCT03981822 · 105 enrolled · United States
- Nov 17, 2025Phase 3 study in WartsNCT07246590 · 302 enrolled · United States
- May 27, 2026Phase 3 study in WartsNCT07637734 · 300 planned · United States, Japan
- Oct 13, 2026Phase 2 study in WartsNCT07881952 · 30 planned · United States
Ahead
- Nov 2026Primary completion: phase 3 study in WartsNCT07246590
- Apr 2027Primary completion: phase 2 study in WartsNCT07881952
- May 2027Primary completion: phase 3 study in WartsNCT07637734
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 8 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07881952Warts · United States | 2 | Not yet recruiting | Apr 2027 | 30 |
| NCT07637734Warts · United States, Japan | 3 | Recruiting | May 2027 | 300 |
| NCT07246590Warts · United States | 3 | Active, not recruiting | Nov 2026 | 302 |
| NCT03981822Condylomata Acuminata · United States | 2 | Completed | May 21, 2020 | 105 |
| NCT03487549Warts · United States | 2 | Completed | May 16, 2019 | 56 |
| NCT03377803Molluscum Contagiosum · United States | 3 | Completed | Sep 26, 2018 | 262 |
| NCT03377790Molluscum Contagiosum · United States | 3 | Completed | Nov 26, 2018 | 266 |
| NCT03186378Molluscum Contagiosum · United States | 2 | Completed | Jun 25, 2018 | 33 |
How it is read
Names in the registry
- “VP-102”, 2 entries
- “VP-102 - Cantharidin, Topical Film Forming Solution”, 2 entries
- “VP-102 (US) / TO-208 (Japan)”, 1 entry
- “VP-102 and applicator”, 1 entry
- “VP-102 Cantharidin topical film forming solution”, 1 entry
Codes read as this program: VP102.
Conditions, from the studies’ own filings
- Warts, 4 studies
- Molluscum Contagiosum, 3 studies
- Condylomata Acuminata, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.